CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls

Cardinal Health reported mixed Q4 FY25 results, with adjusted EPS of $2.08 beating consensus by 2.5% and rising 13% year-over-year, while revenue of $60.2 billion was flat and missed estimates. Despite the top-line miss, the company achieved broad-based profit growth, notably a 19% increase in adjusted operating income and strong segment-level gains, prompting management to raise its fiscal 2026 adjusted EPS guidance to $9.30-$9.50. However, shares declined 10.6% in pre-market trading, reflecting investor reaction likely to the revenue miss despite the positive earnings beat and outlook raise.

Analysis

Cardinal Health reported divergent fiscal Q4 2025 results, characterized by strong profitability and forward guidance despite a top-line miss. While revenue was flat year-over-year at $60.2 billion and missed consensus by 0.8%, this figure was skewed by the known expiration of its OptumRx contract; excluding this impact, the core Pharmaceutical segment's sales grew a robust 22%. The key takeaway is the significant improvement in profitability, with adjusted EPS of $2.08 beating estimates and growing 13% YoY. This was driven by broad-based strength, evidenced by a 19% increase in adjusted operating income to $719 million and a 50-basis-point expansion in gross margin to 3.7%. All segments contributed to profit growth, with the Pharmaceutical segment up 11% and the smaller Medical and Other segments posting substantial gains. Management's confidence is clearly signaled by the decision to raise fiscal 2026 adjusted EPS guidance to a range of $9.30-$9.50, which is above the prior outlook and current consensus. The 10.6% pre-market share price decline suggests the market is heavily weighing the headline revenue miss, potentially overlooking the underlying operational strength and creating a disconnect with the positive earnings outlook.

Key Decisions for Investors

• Investors should look past the headline revenue miss and focus on the superior profitability metrics, including the 19% growth in adjusted operating income and the impressive 22% underlying sales growth in the Pharmaceutical segment excluding the disclosed contract loss.
• The raised fiscal 2026 EPS guidance to a range above consensus estimates is a strong bullish signal and should be the primary driver for valuation, indicating management's high degree of confidence in sustained operational momentum.
• The sharp negative pre-market reaction may represent a buying opportunity for investors with a long-term horizon, as it appears disconnected from the strong fundamental performance and positive outlook, though the stock's prior 33.1% year-to-date run-up warrants consideration for potential profit-taking pressures.